Russell Investments Group Ltd. Increases Stock Position in Arvinas, Inc. $ARVN

Russell Investments Group Ltd. increased its position in Arvinas, Inc. (NASDAQ:ARVN) by 444.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,549 shares of the company’s stock after purchasing an additional 33,922 shares during the quarter. Russell Investments Group Ltd. owned 0.06% of Arvinas worth $292,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new position in shares of Arvinas in the fourth quarter valued at $28,000. GAMMA Investing LLC boosted its stake in shares of Arvinas by 11,283.8% in the first quarter. GAMMA Investing LLC now owns 4,212 shares of the company’s stock valued at $300,000 after purchasing an additional 4,175 shares during the period. CWM LLC boosted its stake in shares of Arvinas by 2,317.5% in the first quarter. CWM LLC now owns 7,615 shares of the company’s stock valued at $53,000 after purchasing an additional 7,300 shares during the period. Aigen Investment Management LP purchased a new position in shares of Arvinas in the first quarter valued at $77,000. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of Arvinas in the first quarter valued at $80,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ARVN shares. Leerink Partnrs downgraded shares of Arvinas from a “strong-buy” rating to a “hold” rating in a research note on Sunday, June 1st. UBS Group cut their price target on shares of Arvinas from $74.00 to $21.00 and set a “buy” rating on the stock in a report on Thursday, May 15th. Leerink Partners reaffirmed a “market perform” rating and issued a $9.00 price target (down from $10.00) on shares of Arvinas in a report on Monday, June 2nd. Morgan Stanley cut their price target on shares of Arvinas from $12.00 to $11.00 and set an “equal weight” rating on the stock in a report on Friday, May 9th. Finally, Wells Fargo & Company cut their price target on shares of Arvinas from $19.00 to $16.00 and set an “overweight” rating on the stock in a report on Thursday, August 7th. Twelve analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $19.76.

Insider Buying and Selling at Arvinas

In other Arvinas news, CFO Andrew Saik sold 5,700 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $7.61, for a total transaction of $43,377.00. Following the sale, the chief financial officer directly owned 164,401 shares of the company’s stock, valued at approximately $1,251,091.61. This represents a 3.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.73% of the company’s stock.

Arvinas Stock Performance

Shares of NASDAQ:ARVN opened at $7.73 on Tuesday. The stock has a market capitalization of $567.54 million, a price-to-earnings ratio of -7.65 and a beta of 2.38. Arvinas, Inc. has a 1-year low of $5.90 and a 1-year high of $29.61. The company’s fifty day moving average is $7.49 and its two-hundred day moving average is $8.64.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Wednesday, August 6th. The company reported ($0.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.03. The company had revenue of $22.40 million for the quarter, compared to analysts’ expectations of $34.42 million. Arvinas had a negative net margin of 19.47% and a negative return on equity of 12.01%. The firm’s revenue was down 70.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.49) earnings per share. Sell-side analysts expect that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.